2C-MMDA-2


2C-MMDA-2, also known as MMDPEA-2 or 6-methoxy-MDPEA, as well as 2-methoxy-4,5-methylenedioxyphenethylamine, is a serotonin 5-HT2 receptor agonist of the phenethylamine and methylenedioxyphenethylamine families. Along with lophophine, it is one of the positional isomers of methoxymethylenedioxyphenethylamine. 2C-MMDA-2 is also the phenethylamine analogue of MMDA-2.

Use and effects

In his book PiHKAL, Alexander Shulgin described testing 2C-MMDA-2 at doses of up to 2.6mg and observed no effects but did not try higher doses.

Pharmacology

Pharmacodynamics

2C-MMDA-2 is a full agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. Its values were 148nM for Gq signaling and 589nM for β-arrestin2 signaling at the serotonin 5-HT2A receptor, 204nM at the serotonin 5-HT2B receptor, and 9.77nM at the serotonin 5-HT2C receptor. 2C-MMDA-2 was more potent as a serotonin 5-HT2 receptor agonist than mescaline.

Chemistry

Analogues

The NBOMe derivative of 2C-MMDA-2 is 2C2-NBOMe. It is a highly potent serotonin 5-HT2 receptor agonist and produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.

History

in tested 2C-MMDA-2 in 1963. He described these findings in his 1991 book PiHKAL, which is when 2C-MMDA-2 appears to have been first described in the literature. Later, 2C-MMDA-2 was assessed in terms of serotonin receptor activity by Jason Wallach and colleagues in 2023.